#PRX115
August 14, 2026 at 2:46 AM
Protalix reports 1Q
*Revs $34mm (includes $25mm milestone)
*2026 guidance of $78-83mm affirmed
*EPS 22c
*$51mm in cash
*PRX115 topline in 2H27
*Call @ 8 am ET
#$PLX
ir.protalix.com/news-release...
ir.protalix.com
May 13, 2026 at 11:25 AM
Protalix CEO Dror Bashan pens letter to stockholders emphasizing:
*Development
~Ph2 PRX115
~Renal pipeline-PRX119
~Secarna OligoCreator
*Chiesi, Elfabrio & CHMP flexible dosing
*Dec'25 BioMarin/Amicus Galafold acq
*Elelyso
$PLX
ir.protalix.com/news-release...
Protalix BioTherapeutics Letter to Stockholders | Protalix BioTherapeutics
ir.protalix.com
January 5, 2026 at 2:20 PM
Protalix_Bio CEO Dror Bashan pens shareholder letter & addresses:
*EMA dosing submission
*PRX115
*PRX119
*ProCellEx & renal rare disease
*Elfabrio & Elelyso
*Debt repaid
$PLX
finance.yahoo.com/news/protali...
Protalix BioTherapeutics Issues 2025 Letter to Stockholders
Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its propri...
finance.yahoo.com
December 23, 2024 at 5:03 PM